Peptide & experimental
BPC-157
Synthetic pentadecapeptide (gastric mucosa derivative) · Body Protection Compound 157, PL 14736
BPC-157 is a synthetic pentadecapeptide sold as a repair agent for tendons, ligaments and the gut lining. The decisive finding is a negative one: not a single published randomized controlled trial in humans exists.
What BPC-157 is
BPC-157 consists of 15 amino acids and is derived from a protective protein that occurs naturally in gastric juice. It is considered exceptionally acid-stable. In animal models, the described effects are attributed to the FAK/paxillin signaling pathway, that is, the migration of fibroblasts and tendon cells and type I collagen synthesis, as well as to the VEGFR2/eNOS/NO axis with new blood vessel formation and improved blood flow.
This description of the mechanism is detailed and plausible, but it comes almost entirely from rodent models and ex vivo tissue. A mechanism of action in animals says nothing about whether a substance works in humans and how safe it is over months.
The negative finding and how it was reached
So that the statement remains verifiable, the searches carried out are documented here. In Europe PMC, the search for BPC-157 human returned 575 hits, consisting exclusively of reviews, animal studies in rats and ex vivo tissue. The search (BPC 157 OR BPC-157) AND (clinical trial OR randomized) returned 50 hits, not one of which was a human study.
The search (BPC 157 OR BPC-157) AND (patients OR volunteers) AND PUB_TYPE:Clinical Trial returned zero hits. BPC 157 AND phase I returned 14 hits, all of them reviews. BPC 157 AND (human subjects OR healthy volunteers) returned 21 hits, reviews and rat studies. BPC 157 AND ulcerative colitis clinical returned 69 hits from reviews, commentaries and case reports. None of these searches turned up a randomized controlled trial in humans.
What is well supported
- The preclinical base is extensive. A systematic review searching PubMed, Cochrane and Embase up to 2024-06-03 identified 544 articles and included 36. 35 of them are preclinical studies. More than three decades of research are thus available — they concern animal models and ex vivo tissue, not humans.
- A randomized phase 2 trial in humans is underway. NCT07437547 on hamstring strain has been recruiting since 2026-02-02 and is designed for 120 participants; completion is estimated for February 2028. Until then, no randomized controlled efficacy data in humans are to be expected. A phase 1 trial on the rotator cuff with 30 participants is also registered but not yet recruiting.
- The proposed mechanism of action is described. The effects are attributed to the FAK/paxillin signaling pathway (migration of fibroblasts and tendon cells, type I collagen synthesis) and the VEGFR2/eNOS/NO axis (new blood vessel formation), plus a dampening of NF-κB and COX-2. The peptide is acid-stable. This description comes from the same models as the rest of the data and does not replace proof of efficacy.
What the studies show
Systematic review: a single clinical paper
A systematic review searched PubMed, Cochrane and Embase from database inception to June 3, 2024, identified 544 articles and included 36. Of these, 35 were preclinical. The one clinical paper is a retrospective case series on intra-articular injection for nonspecific chronic knee pain, in which 7 of 12 patients reported relief over six months: without randomization, without a control group, without blinding. On safety, the review states verbatim that no clinical safety data were found.
Scoping review: three pilot studies in total
A second review counts three pilot studies in humans in total: on intra-articular knee pain, on interstitial cystitis, and on intravenous safety and pharmacokinetics. The authors describe the human data as extremely limited and classify the substance as investigational.
The field as a whole: two thirds animal models
A PRISMA scoping review of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu found that 67 % of all publications on these substances used preclinical animal models. Human clinical studies were limited to a handful of investigations, most of which lacked robust controls or rigorous study design. Another review notes that despite more than three decades of preclinical research, there is no approved formulation, no validated dosing regimen and no completed phase II trial.
Registry status: four entries, results in 2028 at the earliest
ClinicalTrials.gov lists four entries in total. NCT02637284, a phase 1 study in healthy volunteers with 42 planned participants, started in October 2015, was due to end in March 2016, has the status UNKNOWN, was last updated on 2015-12-17 and has no results posted. NCT07437547 is a phase 2 trial on hamstring strain with 120 planned participants, recruiting since 2026-02-02, with estimated completion 02/2028. NCT07803250 on the rotator cuff is phase 1 with 30 participants and not yet recruiting. NCT07752381 is listed as completed, but was single-arm without placebo, included 40 participants over eight weeks, tested a commercial gummy and has no results posted.
Where the data stop
- Faster healing of tendons and ligaments in humans. This claim rests on rodent models. A controlled human study that would test it does not exist.
- Effect in ulcerative colitis or other bowel diseases. The relevant search turned up reviews, commentaries and case reports, not a randomized controlled trial.
- Safety in humans. The systematic review states verbatim that no clinical safety data were found. The only registered phase 1 study in healthy volunteers never published results.
- Pharmaceutical quality of the products sold. BPC-157 is sold on the gray market as a substance for research purposes only, outside any drug regulation.
Status, approval and legal
BPC-157 is not an approved medicine. There is no approved formulation, no validated dosing regimen and no completed phase II trial. In competitive sports the substance is banned by WADA.
The only ongoing phase 2 trial, NCT07437547 on hamstring strain, has been recruiting since 2026-02-02 and will be completed in February 2028 at the earliest. Until then, the evidence will not change: no randomized controlled efficacy data in humans are to be expected before 2028.
Safety
No reliable safety data exist. The 2025 systematic review explicitly states that no clinical safety data were found. The phase 1 study in 42 planned healthy volunteers, started in 2015, has posted neither an update nor results since December 2015.
The only registry study listed as completed was single-arm without placebo, included 40 participants over eight weeks and tested a commercial gummy; results are missing there too. Under these circumstances, the absence of reported side effects is not proof of safety but a lack of data.
BK-Score Tested in humans, results unpublished
| Human evidence | 1 | |
|---|---|---|
| Mechanism | 4 | |
| Safety data | 2 | |
| Hype gap | 1 | |
| Track record of use | 5 |
The case shows the difference between “never tried in humans” and “tried, result never published”: the Croatian manufacturer Pliva conducted phase II studies (PL-14736) in ulcerative colitis that reportedly showed positive effects without toxicity – the full data were never published as a stand-alone clinical paper and therefore cannot be verified. A phase I study in 42 healthy volunteers (NCT02637284) was terminated in 2016 without results. To this day, no published randomized controlled trial in humans exists for any indication; the reliable data consist of rodent models. Use, by contrast, is real and extensive: in the US, BPC-157 was produced for years in compounding pharmacies and used in sports and rehab practices. In 2023 the FDA placed it in Category 2 due to immunogenicity and impurities, removed it from that category on April 15, 2026, and on July 24, 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 to add it to Category 1 for the indication ulcerative colitis – non-binding, and it cannot currently be produced legally. It is sold as a repair agent for almost every tissue. So the track record of use is considerable – it does not replace the missing evidence.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about BPC-157
Are there studies on BPC-157 in humans?
No published randomized controlled trial in humans exists. A systematic review identified 544 articles and included 36, thirty-five of them preclinical. The only clinical paper is a retrospective case series with twelve patients, without a control group and without blinding. Several targeted database searches for clinical trials returned not a single hit in humans.
Does BPC-157 really work for tendon injuries?
That is not established. The efficacy for tendons, ligaments and muscle tears comes from animal models, mostly in rats. Two thirds of all publications on this group of substances use preclinical animal models. A study that randomized humans against placebo and tested this claim has not been published.
Is BPC-157 approved in Germany?
No. BPC-157 is not an approved medicine. There is no approved formulation, no validated dosing regimen and no completed phase II trial, despite more than three decades of preclinical research. The substance is traded as a research chemical outside drug regulation. In competitive sports it is banned by WADA.
What side effects does BPC-157 have?
That is unknown, and that is the real point. The 2025 systematic review explicitly states that no clinical safety data were found. The only registered phase 1 study in healthy volunteers started in 2015 and never published results. Without data, neither safety nor danger can be demonstrated.
When will there finally be reliable data on BPC-157?
In 2028 at the earliest. The only ongoing phase 2 trial is studying hamstring strain with one hundred twenty planned participants, has been recruiting since February 2, 2026, and lists an estimated completion in February 2028. Another phase 1 trial on the rotator cuff with thirty participants has not yet started recruiting.
Why is BPC-157 so widespread anyway?
The track record of use is extensive; the evidence is not. Here the two diverge. For years, sports and rehabilitation practices and user communities have consistently reported faster healing of tendons, ligaments and the gut. Such reports are uncontrolled and unblinded; they do not replace a randomized trial.
The podcast episode (in German)
Episode 36
AI podcast: The Wolverine Stack – BPC-157 + TB-500 (regeneration duo)
The podcast by Paul Höser (Episode 36). AI-generated German episode (Paul & Paula) with expert research on the “Wolverine Stack” (BPC-157 + TB-500) – how the two peptides complement each other via different signaling pathways in different phases of healing. Information only – not medical advice, no dosage or usage recommendation. Research peptides, not approved as medicines, banned in sports (WADA).
Related
- Same substance classPentadeca Arginate (PDA)
Sources
- Vasireddi et al. 2025, HSS Journal – systematic review, 544 articles, 36 included, 35 preclinical (PMID 40756949)
- McGuire et al. 2025, Current Reviews in Musculoskeletal Medicine – scoping review, three pilot studies in humans (PMID 40789979)
- Mateescu et al. 2026, Pharmaceutics – no approved formulation, no completed phase II trial (PMID 42198317)
- Tewari et al. 2026, American Journal of Sports Medicine – PRISMA scoping review, 67 % preclinical animal models (PMID 42578445)
- ClinicalTrials.gov – NCT02637284, phase 1 in healthy volunteers, status UNKNOWN, no results
- ClinicalTrials.gov – NCT07437547, phase 2 hamstring strain, estimated completion 02/2028
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-13.